Form 4: ALX Oncology Director Barbara Klencke Acquires Stock Options

Director Barbara Klencke of ALX Oncology Holdings Inc. was granted stock options for 40,400 shares on January 21, 2025.

Summary

• Barbara Klencke, a director at ALX Oncology Holdings Inc., was granted stock options to purchase 40,400 shares of common stock.
• The options have an exercise price of $1.65 per share.
• The options vest in 36 equal monthly installments starting on February 21, 2025.
• The options expire on January 20, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There is no indication of any negative or unexpected events.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

This is a standard practice for incentivizing directors in publicly traded companies, particularly in the biotech sector.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors in publicly traded companies, especially in the biotechnology industry.
• The vesting schedule of 36 months is typical for such grants, aligning with industry standards for long-term incentives.
• The exercise price of $1.65 is specific to ALX Oncology and would need to be compared to the current market price of the stock to assess its value.

Stakeholder Impact

• The granting of stock options to a director aligns their interests with those of the shareholders, potentially leading to better performance and increased shareholder value.

Key Dates

Keywords

stock options, insider trading, beneficial ownership, ALX Oncology, director, equity